Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase–rearranged Advanced Non–Small Cell Lung Cancer Patients Treated With Crizotinib

Conclusions: The 8-week tumor volume decrease of>74% is significantly associated with longer OS in patients with ALK-rearranged NSCLC treated with crizotinib.
Source: Journal of Thoracic Imaging - Category: Radiology Tags: Original Articles Source Type: research